



AMENDMENTS TO THE CLAIMS

1. (Previously Presented) A cyclic peptide having the formula:




wherein B is a bridge moiety selected from:


i)




ii)




iii)




iv)




v)




vi)




vii)




viii)




ix)



2. (Previously Presented) A compound according to Claim 1 having the following stereochemical formula:




3. (Previously Presented) A cyclic peptide having the formula:




wherein B is a bridge moiety selected from:


i)




ii)




iii)




iv)




v)




vi)




vii)



viii)




ix)




; and

x)




4. (Previously Presented) A compound according to Claim 2 having the following stereochemical formula:




5. (Previously Presented) A composition comprising:

A) one or more cyclic peptides having the formula:




wherein B is a bridge moiety selected from:


i)




ii)




iii)




iv)




v)




vi)




vii)



viii)




ix)




B) one or more excipients.

6. (Previously Presented) A composition according to Claim 5 wherein said cyclic peptides have the following stereochemical formula:




7. (Previously Presented) A composition comprising:

A) one or more cyclic peptides having the formula:




wherein B is a bridge moiety selected from:


i)




ii)




iii)




iv)




v)




vi)




vii)




viii)



ix)




x)




B) one or more excipients.

8. (Previously Presented) A composition according to Claim 7 wherein said cyclic peptides have the following stereochemical formula:




9. (Currently Amended) A method of stimulating the melanocortin-4 (MC-4) receptor in a mammal comprising administering to a mammal in need thereof a composition comprising a cyclic peptide, for a time and under conditions effective to stimulate the MC-r receptor, said ~~for treating obesity, said method comprising the step of contacting a human or higher mammal with a composition comprising:~~

A) one or more cyclic peptides having the formula:




wherein B is a bridge moiety selected from:


i)




ii)




iii)




iv)




v)




vi)




vii)



viii)




ix)



B) one or more excipients.


10. (Currently Amended) A method for suppressing appetite in a human who is endeavoring to reduce caloric intake comprising administering to said human a composition comprising a cyclic peptide, for a time and under conditions effective to stimulate the melanocortin-4 receptor, said ~~treating obesity, said method comprising the step of contacting a human or higher mammal with a composition~~ comprising:

A) one or more cyclic peptides having the formula:




wherein B is a bridge moiety selected from:


i)




ii)




iii)




iv)




v)




vi)




vii)




viii)



ix)



x)



B) one or more excipients.